Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Rhea-AI Summary

Quantum BioPharma (NASDAQ: QNTM) announced a peer‑reviewed publication (World Journal of Pharmaceutical and Medical Research, March 23, 2026) reporting a double‑blind, randomized, placebo‑controlled crossover trial of its dietary supplement unbuzzd.

Key findings: >40% faster reduction in blood alcohol concentration within 30 minutes, improved alertness and physiologic stability, 67% reduction in headache severity at four and eight hours, and no reported adverse side effects.

Positive

• BAC reduction >40% faster within 30 minutes
• Headache severity down 67% at 4 and 8 hours
• Statistically significant improvements vs placebo in alertness and physiologic measures
• Peer-reviewed publication in an international journal confirming clinical trial results
• No reported adverse effects in study participants

Negative

• Not an FDA drug approval; unbuzzd is described as a dietary supplement
• Does not permit driving; consuming unbuzzd after alcohol does not make operating a vehicle safe
• Individual results may vary, per company disclosure

News Market Reaction – QNTM

+38.39% 7.3x vol

62 alerts

+38.39% News Effect

+123.7% Peak in 30 hr 26 min

+$5M Valuation Impact

$18M Market Cap

7.3x Rel. Volume

On the day this news was published, QNTM gained 38.39%, reflecting a significant positive market reaction. Argus tracked a peak move of +123.7% during that session. Our momentum scanner triggered 62 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $18M at that time. Trading volume was exceptionally heavy at 7.3x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

BAC target range: 0.07%–0.11% BAC Alcohol reduction speed: More than 40 percent faster Headache reduction: 67 percent reduction +5 more

8 metrics

BAC target range 0.07%–0.11% BAC Intoxication level before unbuzzd or placebo dosing in trial

Alcohol reduction speed More than 40 percent faster Average BAC reduction rate within first 30 minutes vs. placebo

Headache reduction 67 percent reduction Decrease in headache severity at 4 hours vs. placebo

Follow-up duration Four-hour period Continued BAC measurements after dosing

Participant age range 21–43 years Healthy male and female participants in unbuzzd trial

Weight range 119–232 pounds Body weight range of study participants

Malone ownership 9.8% of shares Schedule 13G/A reporting 375,752 shares beneficially owned

ATM size US$21,225,000 Prospectus supplement for ATM offering of Class B shares

Market Reality Check

Price: $4.73 Vol: Volume 72,764 is well bel...

low vol

$4.73 Last Close

Volume Volume 72,764 is well below the 20-day average 273,957 (relative volume 0.27). low

Technical Shares at $2.24 are trading below the 200-day MA of $12.92 and 94.14% under the 52-week high.

Peers on Argus

QNTM fell 5.08% while momentum peers like MNOV and INKT also moved down (median ...

2 Down

QNTM fell 5.08% while momentum peers like MNOV and INKT also moved down (median peer move about -4.2%), indicating broader Healthcare/Biotech pressure.

Previous Clinical trial Reports

5 past events · Latest: Oct 02 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Oct 02	Lucid-MS study reports	Positive	+9.5%	Final 90-day toxicity and toxicokinetic reports support IND and planned Phase 2.
Oct 01	Advisor appointment	Positive	+0.8%	MS expert Dr. Jack Antel joins as advisor for Lucid-MS clinical development.
Aug 11	Manufacturing agreement	Positive	-10.1%	CDMO deal to manufacture oral Lucid-MS formulation for upcoming Phase 2 trial.
Aug 05	Phase 1 MAD results	Positive	-11.6%	Phase 1 MAD trial shows Lucid-MS safety and tolerability in healthy participants.
May 28	FSD202 Phase 2 greenlight	Positive	+1.5%	Ethics approval for Phase 2 FSD202 trial in MCAS-related nociplastic pain.

Pattern Detected

Clinical and development milestones have produced mixed reactions, with both strong gains and notable selloffs around trial updates.

Recent Company History

Over the past year, Quantum BioPharma has repeatedly highlighted its clinical pipeline. For Lucid-MS, it reported Phase 1 MAD safety, manufacturing preparations for an oral formulation, and final reports from 90‑day toxicity and toxicokinetic studies, all supporting a future IND and planned Phase 2 trials. It also secured ethics approval for a Phase 2 trial of FSD202 in MCAS-related nociplastic pain. Today’s peer‑reviewed publication for unbuzzd adds a separate, clinically supported product to this history of trial-driven announcements.

Historical Comparison

-2.0% avg move · Past clinical-trial headlines for QNTM led to an average -1.99% move, showing that even positive stu...

clinical trial

-2.0%

Average Historical Move clinical trial

Past clinical-trial headlines for QNTM led to an average -1.99% move, showing that even positive study updates often met with cautious trading.

Clinical news has tracked steady progression: Lucid-MS advancing from Phase 1 safety to Phase 2-enabling work, while FSD202 moved into Phase 2 ethics-approved study design.

Market Pulse Summary

The stock surged +38.4% in the session following this news. A strong positive reaction aligns with Q...

Analysis

The stock surged +38.4% in the session following this news. A strong positive reaction aligns with Quantum BioPharma’s pattern of market interest in clinical milestones, as seen around prior Lucid-MS updates. However, the stock’s position 94.14% below its 52‑week high and past negative moves after some trial news suggest that enthusiasm could fade. Investors monitoring sustainability may focus on how this peer‑reviewed unbuzzd data integrates with the broader pipeline and past financing dynamics.

Key Terms

double-blind, randomized, placebo-controlled, crossover design, +2 more

6 terms

double-blind medical

"peer-reviewed publication of the double-blind, randomized, placebo-controlled crossover design clinical trial"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

randomized medical

"peer-reviewed publication of the double-blind, randomized, placebo-controlled crossover design clinical trial"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

placebo-controlled medical

"peer-reviewed publication of the double-blind, randomized, placebo-controlled crossover design clinical trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

crossover design medical

"peer-reviewed publication of the double-blind, randomized, placebo-controlled crossover design clinical trial"

A crossover design is a clinical trial setup where each participant receives two or more treatments one after the other, with a break between them, so the same person serves as their own comparison. Think of it like trying two recipes in the same kitchen to judge which is better. For investors, this matters because it can make results clearer with fewer participants and faster readouts, but it can also be inappropriate for long‑lasting effects, which affects how reliable the efficacy and safety data will be for regulatory and commercial decisions.

blood alcohol concentration medical

"Participants first drank measured quantities of alcohol to achieve a Blood Alcohol Concentration (“BAC”)"

Blood alcohol concentration is the amount of alcohol present in a person’s bloodstream, expressed as a proportion of blood; think of it like measuring how much sugar is dissolved in a cup of tea. It matters to investors because BAC levels drive legal limits, safety rules and liability exposure for businesses, influence regulatory penalties and insurance costs, and can affect workforce safety, product use and public reputation—factors that can change a company’s costs and earnings.

statistically significant technical

"These results were statistically significant compared to placebo."

"Statistically significant" means that a result or difference observed in data is unlikely to have occurred by chance alone, suggesting there is a real underlying effect. For investors, it indicates that the findings or patterns they see are likely meaningful and not just random noise, helping them make more informed decisions based on reliable information. Think of it as a pattern that is strong enough to stand out clearly from background randomness.

AI-generated analysis. Not financial advice.

unbuzzd Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover

TORONTO, March 23, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced the peer-reviewed publication of the double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product, ‘unbuzzd’, comprising of a proprietary blend of vitamins and supplements developed by a world-class team of scientists at Quantum BioPharma. The trial, which investigated the effects of unbuzzd on alcohol intoxication and alcohol metabolism, was published here in the World Journal of Pharmaceutical and Medical Research (2026, volume 12, issue 3, pages 446-467).

The publication can be viewed by clicking the following link: https://zenodo.org/records/18873638

The clinical trial, designed to mirror real-life situations where people would consume unbuzzd after reaching an alcohol inebriated state included healthy male and female study participants between the ages of 21 and 43, with weights ranging from 119 to 232 pounds. Participants first drank measured quantities of alcohol to achieve a Blood Alcohol Concentration (“BAC”) between 0.07% and 0.11% followed by ingestion of either unbuzzd or placebo. BAC was then further monitored as well as vital signs and symptoms of intoxication. unbuzzd accelerated the rate at which BAC was reduced in participants, while simultaneously reducing the symptoms of intoxication, impairment and hangover. These results were statistically significant compared to placebo.

Key findings from the clinical trial include:

• Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was on average for most participants more than 40 percent faster within the first 30 minutes of consuming unbuzzd compared to when participants consumed placebo.
• The faster reduction of BAC after consuming unbuzzd was statistically significant compared to the placebo and was observed in both males and females as shown in the figure below from the publication (note: FSD-F2R6 is the scientific name of the unbuzzd formulation). The continued acceleration of alcohol metabolism was also seen at subsequent BAC measurements over a four-hour period.

• Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert making fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results.
• Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was noted as statistically significant.
• Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.
• Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd.
• No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.
  
  

“The unbuzzd clinical trial has now been published in a peer-reviewed international journal, and the trial confirms the exceptional overall efficacy of unbuzzd to help reduce the acute effects of alcohol intoxication and hangover, all without causing adverse side effects,” said Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs at Quantum Biopharma. “We are thrilled to report this outcome.”

Anthony Durkacz, Founder and Executive Co-Chairman of Quantum BioPharma added, “The science and medical communities for centuries have believed there is no way to significantly speed up alcohol metabolism once it is in your bloodstream; your liver processes it at a largely constant rate of approximately one standard drink per hour, and that the only sobering agent is time. This publication validates unbuzzd as a responsible aid to reduce BAC, alleviate signs of alcohol intoxication, and assists with the dreaded hangover. Consumers can use unbuzzd knowing there is a peer-reviewed scientific publication with clinical trial evidence of the product’s efficacy.”

The formula for unbuzzd is licensed to Unbuzzd Wellness Inc. and is currently available at www.unbuzzd.com and www.amazon.com. unbuzzd is a registered trademark of Unbuzzd Wellness Inc.

Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.

About Unbuzzd Wellness Inc.

Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.

unbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and 18-pack formats at https://unbuzzd.com.

Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.

8-pack, 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks

To view an enhanced version of this graphic, please visit: link

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of 19.86% (as of September 30, 2025) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum BioPharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Forward-Looking Information

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.

Contacts:

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (416) 854-8884

Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/600ca40f-b94f-49bc-8d5f-5ff43576b965

https://www.globenewswire.com/NewsRoom/AttachmentNg/213c2b0f-182e-4ac0-b562-031c143ed6cf

FAQ

What did Quantum BioPharma (QNTM) announce on March 23, 2026 about unbuzzd?

Quantum BioPharma announced a peer‑reviewed clinical trial publication showing unbuzzd reduced BAC and intoxication symptoms. According to Quantum BioPharma, the double‑blind crossover trial showed >40% faster BAC reduction and statistically significant symptom improvements versus placebo.

How much did unbuzzd speed blood alcohol concentration (BAC) reduction in the QNTM study?

unbuzzd reduced BAC more than 40% faster within the first 30 minutes for most participants. According to Quantum BioPharma, accelerated BAC reduction was statistically significant versus placebo and persisted across subsequent measurements over four hours.

Did the QNTM clinical trial report improvements in hangover and symptoms of intoxication?

Yes, the trial reported significant reductions in intoxication, impairment, mental fatigue and hangover symptoms. According to Quantum BioPharma, headache severity fell 67% at four and eight hours compared with placebo in the study.

Were there safety concerns reported in the March 23, 2026 QNTM unbuzzd trial?

No adverse side effects were reported in the published trial; unbuzzd was described as well tolerated. According to Quantum BioPharma, study participants experienced no reported adverse events during the randomized crossover study.

Can consumers drive after taking unbuzzd following alcohol consumption, per Quantum BioPharma (QNTM)?

No; consuming unbuzzd after alcohol ingestion does not permit operating a vehicle. According to Quantum BioPharma, users are warned that unbuzzd is a dietary supplement and does not make driving safe after drinking.